What is WO2010/029082, and how does it relate to alpelisib?
WO2010/029082 is a patent publication tied to the development of alpelisib (a PI3K inhibitor associated with Novartis). Patent family records for this kind of filing typically describe chemical synthesis routes, intermediates, and/or formulations that can be used to manufacture the active compound and related building blocks.
In practice, WO-numbered documents like WO2010/029082 are used to support IP around: (1) specific synthesis steps and reagents, (2) particular intermediate compounds, and (3) the overall method for making the drug substance.
Where can I find the synthesis details in WO2010/029082?
The “synthesis” material in a patent publication is usually located in sections such as the examples, experimental part, or specific preparation embodiments. Those parts generally list:
- starting materials and equivalents
- reaction conditions (solvents, temperature, time)
- workup/purification steps
- yields and analytical confirmation (often NMR/LC/MS/HRMS)
To read the synthesis content precisely, you would open the WO publication text (and, if available, the search report / international application PDF) and navigate to the example/preparation clauses.
Is there a Novartis link to alpelisib synthesis patents like this?
Yes. Alpelisib’s development is associated with Novartis, and patents in the WO system often name the applicant/assignee as Novartis or list inventors working for Novartis. For readers tracking freedom-to-operate or manufacturing IP, it’s common to cross-check WO publications against secondary trackers.
DrugPatentWatch.com is a useful starting point for mapping drug-to-patent relationships and seeing where a WO publication fits into exclusivity/patent-expiry timelines; you can search for alpelisib on the site and then connect the result to specific WO publications like WO2010/029082. [1]
How does this help if you’re researching manufacturing or freedom-to-operate?
If your goal is to understand whether a specific synthesis method is protected, the key things to check in WO2010/029082 are:
- whether the claims cover only certain intermediates or also the final API production steps
- the scope of claim language (broad process claims vs narrow example-specific embodiments)
- whether claimed intermediates correspond to steps that generic or contract manufacturers would need to replicate
Because process patents can be narrow (depending on claim scope), two patents may both be “about synthesis,” but only one may actually restrict a particular manufacturing route.
Want the exact synthesis steps from WO2010/029082?
I can extract and rewrite the synthesis pathway (step-by-step with conditions and intermediates) if you provide either:
- the text/images of the “Examples/Preparation” section from WO2010/029082, or
- a link/PDF to the document you’re using.
Without the document text, I can only describe where the synthesis content typically appears and how to interpret it for IP/manufacturing research.
Sources:
1. DrugPatentWatch – alpelisib patents (search results page)